SCHEMBL3485464

SCHEMBL3485464

Cc1cccc2nc(NC(=O)c3ccc(C(C)(C)C(=O)O)cc3)cn12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 12/20 0.57
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
GRM5 P41594 1/20 0.41
CLK2 P49760 2/20 0.41
PDGFRB P09619 1/20 0.41
KIT P10721 1/20 0.41
PDGFRA P16234 1/20 0.41
HRH1 P35367 1/20 0.41
FLT3 P36888 1/20 0.41
CLK1 P49759 1/20 0.41
CLK3 P49761 1/20 0.41
DYRK1A Q13627 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485303 0.89 MAP3K5 (0.67) MAP3K5KDM4ELMNAGAAMAPT
SCHEMBL3485827 0.89 MAP3K5 (0.55) MAP3K5KDM4ELMNAGAAMAPT
Hydrochloric Acid SCHEMBL3486394 0.88 MAP3K5 (0.66) MAP3K5KDM4ELMNAGAAMAPT
SCHEMBL3486573 0.84 MAP3K5 (0.50) MAP3K5KDM4ELMNAGAAMAPT
SCHEMBL13498766 0.79 MAP3K5 (0.80) MAP3K5CLK2PDGFRBKITPDGFRA
SCHEMBL3485656 0.78 MAP3K5 (0.47) MAP3K5KDM4ELMNAGAAMAPT
SCHEMBL3486831 0.77 KDM4E (0.48) MAP3K5KDM4ELMNAGAAMAPT
SCHEMBL3486364 0.76 MAP3K5 (0.51) MAP3K5CLK2PDGFRBKITPDGFRA
SCHEMBL3486220 0.74 MAP3K5 (0.80) MAP3K5CLK2PDGFRBKITPDGFRA
SCHEMBL3486342 0.74 MAP3K5 (0.64) MAP3K5MAPTNPC1RAB9ARET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 EP disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND IRAK1, IL1R1, IRAK2 MAP3K5 42/4885KDM4E 898/4885LMNA 3564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.